Brokers Set Expectations for Neovasc Inc.’s FY2022 Earnings (TSE:NVC)

Neovasc Inc. (TSE:NVCGet Rating) (NASDAQ:NVCN) – Investment analysts at HC Wainwright cut their FY2022 earnings per share (EPS) estimates for shares of Neovasc in a report issued on Tuesday, November 15th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($14.95) per share for the year, down from their prior estimate of ($14.91). HC Wainwright also issued estimates for Neovasc’s Q4 2022 earnings at ($2.57) EPS and FY2023 earnings at ($11.20) EPS.

Neovasc Stock Performance

Neovasc has a 52 week low of C$0.49 and a 52 week high of C$6.07. The stock has a 50 day moving average of C$1.78.

Neovasc (TSE:NVCGet Rating) (NASDAQ:NVCN) last issued its quarterly earnings data on Thursday, November 10th. The company reported C($3.91) EPS for the quarter, missing analysts’ consensus estimates of C($3.67) by C($0.24). The company had revenue of C$1.21 million during the quarter, compared to analysts’ expectations of C$1.37 million.

Insiders Place Their Bets

In other news, Director Paul Geyer acquired 4,486 shares of the business’s stock in a transaction dated Friday, September 16th. The stock was acquired at an average price of C$8.39 per share, for a total transaction of C$37,615.11. Following the completion of the acquisition, the director now directly owns 4,486 shares in the company, valued at approximately C$37,615.11. In the last quarter, insiders acquired 11,757 shares of company stock worth $92,751.

About Neovasc

(Get Rating)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Further Reading

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.